Suppr超能文献

用于基于结构的药物设计的蛋白质结晶。

Protein crystallization for structure-based drug design.

作者信息

Hoffman Isaac D

机构信息

Takeda San Diego, San Diego, CA, USA.

出版信息

Methods Mol Biol. 2012;841:67-91. doi: 10.1007/978-1-61779-520-6_4.

Abstract

The crystallization experiment has one main objective: to obtain diffraction quality crystals. This can be achieved through myriad avenues; here the focus will be on crystallization in support of drug discovery. In drug discovery there are two main paradigms for crystallography: high-throughput, and by any means necessary. Each paradigm requires the investigator to formulate strategies based on different priorities. In the high-throughput environment, the emphasis is on rapid prosecution of a large number of protein targets. In the by any means necessary paradigm the target pool is generally smaller and structural information is absolutely necessary for success. The process of growing diffraction quality protein crystals involves deciding on a crystallization method, initial screening, cryoprotection, initial diffraction analysis, and growth optimization. Furthermore, in structure-based drug design it is necessary to obtain crystal structures of protein-ligand complexes.

摘要

结晶实验有一个主要目标

获得具有衍射质量的晶体。这可以通过无数途径实现;这里将重点关注支持药物发现的结晶过程。在药物发现中,晶体学有两种主要模式:高通量模式和不择手段模式。每种模式都要求研究者根据不同的优先级制定策略。在高通量环境下,重点是快速处理大量蛋白质靶点。在不择手段模式中,靶点库通常较小,而结构信息对于成功来说绝对必要。生长具有衍射质量的蛋白质晶体的过程包括选择结晶方法、初始筛选、冷冻保护、初始衍射分析和生长优化。此外,在基于结构的药物设计中,有必要获得蛋白质-配体复合物的晶体结构。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验